Lung‐specific exosomes for doxorubicin delivery in lung adenocarcinoma therapy

Abstract

AbstractDoxorubicin (DOX) could be utilized to treat lung adenocarcinoma (LUAD), while dose‐limiting cardiotoxicity limits its clinical utilization. MDA‐MB‐231 cell‐derived exosomes show lung‐specific organotropism features. In this study, we aimed to explore the potential of MDA‐MB‐231 cell‐derived exosomes in DOX specific delivery to the lung. MDA‐MB‐231 cell‐derived exosomes were coincubated with to construct for the doxorubicin delivery system (D‐EXO). Exosomes labeled with fluorescein isothiocyanate were incubated with A549 cells or 293T cells, and the engulf and the mean intensity of the fluorescence were detected with immunofluorescence and flow cytometry assay. Cell viability was detected with cell counting kit‐8 (CCK‐8), and cell migration was determined by scratch test. The protein expression was detected by Western blot assay. A549 cell line‐derived xenograft mouse model was constructed to examine the treatment effect of D‐EXO. MDA‐MB‐231 cell‐derived exosomes could be specially taken up by A549 cells with diminished cell viability but not engulfed by 293T cells. D‐EXO inhibited A549 cell migration, and upregulated the protein expression of caspase 3 and cleaved caspase 3 expression, while did not show any inhibition on 293T cells. In vivo orthotopic xenotransplantation model indicated that D‐EXO inhibited tumor growth characterized by diminished tumor weight and improved survival rate. No significant change in body weight was observed after the D‐EXO treatment. In conclusion, D‐EXO proposed in this study could be utilized to treat LUAD with lung‐specific delivery effects to improve the survival rate.